Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(12 years from now) | |
US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(11 years from now) | |
US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(16 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Dec 3, 2027 |
New Chemical Entity Exclusivity (NCE) | Dec 3, 2025 |
NCE-1 date: 2024-12-03
Market Authorisation Date: 03 December, 2020
Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL
16
United States
4
Japan
4
Australia
3
Singapore
3
Morocco
3
China
3
EA
3
Lithuania
3
Canada
3
Israel
3
European Union
2
Brazil
2
Croatia
2
New Zealand
2
Philippines
2
Korea, Republic of
2
Hungary
2
Poland
2
RS
2
Denmark
1
Portugal
1
Uruguay
1
Spain
1
Colombia
1
Norway
1
Argentina
1
Mexico
1
Peru
1
Taiwan, Province of China
1
Slovenia
1
Chile
1
Netherlands
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic